SPONSOR

Fudan University

Total Trials

Recruiting

Phases

Phase 2, Phase 3, Phase 1, Phase 2, Phase 4

Conditions studied: Cancer Melanoma of Skin Acral Melanoma Stage II Melanoma Gastric (Stomach) Cancer Helicobacter Infection Thyroid Cancer Breast Cancer Sentinel Lymph Node Frozen Section

Fudan University is a clinical research sponsor with 55 registered studies on ClinicalTrials.gov, of which 55 are actively recruiting participants. Research covers conditions including Cancer, Melanoma of Skin, Acral Melanoma, Stage II Melanoma.

The trial portfolio spans Phase 2, Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Fudan University

How many clinical trials has Fudan University sponsored?

ClinicalMetric currently tracks 55 clinical trials sponsored by Fudan University, of which 55 are actively recruiting participants. These trials cover conditions including Cancer, Melanoma of Skin, Acral Melanoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Fudan University research focus on?

Fudan University clinical trials span Cancer, Melanoma of Skin, Acral Melanoma, Stage II Melanoma, Gastric (Stomach) Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Fudan University clinical trial?

To participate in a Fudan University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fudan University trials with current recruitment status updated daily.

Fudan University

Frequently Asked Questions — Fudan University

Clinical Trials by Fudan University

Real-World Study of Young Patients With Solid Tumors in China

Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer

The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy

Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer

Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Digital Mind-Body Therapy for Neoadjuvant Breast Cancer

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Selective Neck Dissection Versus Modified Neck Dissection in PTC

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.

PBI for Low-risk Breast Cancer

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib